LMC becomes first in region to offer patients a new heart failure monitoring solution



Lankenau Medical Center is the first facility in the Delaware Valley to implant a new miniaturized, wireless monitoring sensor to manage heart failure (HF). The CardioMEMS HF System is the first and only FDA-approved heart failure monitoring device that has been proven to significantly reduce hospital admissions and improve a patient’s quality of life when used by physicians to manage heart failure. Eric Gnall, DO, an Interventional Cardiologist at LMC, implanted the first monitoring device in a patient in early January.


“We are excited to be the first heart program in the Delaware Valley to offer this innovative technology to our heart failure patients,” said Christopher Droogan, DO, Cardiologist and Medical Director of the Advanced Heart Failure Program at LMC. “When used in conjunction as part of an overall heart failure management program, this technology can decrease the likelihood for a patient’s repeat admission to the hospital, greatly improving their quality of life.”


The CardioMEMS HF System features a sensor that is implanted in the pulmonary artery (PA) during a non-surgical procedure to directly measure PA pressure. Increased PA pressures appear before weight and blood pressure changes, which are often used as indirect measures of worsening heart failure. The new system allows patients to transmit daily sensor readings from their homes to their health care providers allowing for personalized and proactive management to reduce the likelihood of hospitalization.


The CardioMEMS sensor is designed to last the lifetime of the patient and doesn’t require batteries. Once implanted, the wireless sensor sends pressure readings to an external patient electronic system. There is no pain or sensation for the patient during the readings. The CardioMEMS HF System allows the patients to transmit critical information about their heart failure status to a clinician on a regular basis, without the need for additional clinic or hospital visits. This provides clinicians with the ability to detect worsening heart failure sooner and adjust treatment to reduce the likelihood that the patient will need to be hospitalized.


Data from a clinical trial showed that the CardioMEMS technology reduces heart failure hospital admissions by up to 37 percent. The CHAMPION trial studied the effectiveness of the CardioMEMS HF System in New York Heart Association (NYHA) Functional Classification System Class III heart failure patients who had been hospitalized for heart failure in the previous 12 months. Results of the trial demonstrated a statistically significant 28 percent reduction in the rate of heart failure hospitalizations at six months, and 37 percent reduction in heart failure hospitalizations during an average follow-up duration of 15 months.


Roughly 1.4 million patients in the U.S. have NYHA Class III heart failure, and historically these patients account for nearly half of all heart failure hospitalizations. According to the American Heart Association, the estimated direct and indirect cost of heart failure in the U.S. for 2012 was $31 billion and that number is expected to more than double by 2030.


“Lankenau Medical Center and the Lankenau Heart Institute are committed to further advancing cardiac care in our region by pioneering new technologies and procedures for the benefit of our patients,” said Phil Robinson, Lankenau Medical Center president. “Our clinicians maintain an unwavering focus on delivering personalized care and advanced clinical solutions to improve the quality of life for our heart patients.”


The CardioMEMS HF System, from global medical device manufacturer St. Jude Medical, is approved by the U.S. Food and Drug Administration (FDA) for commercial use in the U.S. For more information, visit http://www.heartfailureanswers.com/.


This entry was posted in Clinician News and tagged , . Bookmark the permalink.

Leave a Reply

Your email address will not be published.